Faculty

 
 


Stuart N. Isaacs, M.D.

Dr. Isaacs’ laboratory focuses on using poxviruses as a model system to study viral proteins that are involved in viral pathogenesis, dissemination, and evasion of the host immune response. Poxviruses, which are used widely as a tool for research and vaccine development, express proteins that inhibit complement activation, bind IL-1, TNF, and interferons, and decrease the host inflammatory response by other mechanisms. Elucidation of these processes could lead to a safer virus vector. Furthermore, the study of these defense molecules encoded by the virus might give insights into the control of inflammation, as well as, the development of new anti-inflammatory drugs. The laboratory has also been pursuing the use of vaccinia virus as a vaccine vector. They are investigating a novel way of targeting foreign antigens to the outer envelope of the vaccinia virion. Presentation of antigens in this manner may result in enhanced immunity against the foreign antigen when compared to standard vaccinia viruses vectors. The lab is also involved with anti-bioterrorism research. Dr. Isaacs is the poxvirus program project leader for the Middle-Atlantic Regional Center of Excellence in Biodefense and Emerging Infectious Diseases. His lab is developing novel therapies to treat smallpox and complications from the smallpox vaccine. This work involves techniques in molecular biology, construction of recombinant viruses, studies of protein expression and isolation, development, screening, and characterization of monoclonal antibodies, and investigations of viral pathogenesis in laboratory animals.

Bell, E., Shamim, M., Whitbeck, J.C., Sfyroera, G., Lambris, J.D., Isaacs, S.N. Antibodies against the extracellular enveloped virus (EEV) B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin (VIG) Virology Vol. 325: 425– 431, 2004.

Viner, K.M., Isaacs, S.N. “Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccines” Microbes and Infection Vol 7:579-83, 2005.

Empig, C. Kenner, J.R., Perret-Gentil, M., Youree, B.E., Bell, E., Chen, A., Gurwith, M., Higgins, K., Lock, M., Rice, A.D., Schriewer, J., Sinangil, F., White, E., Buller, R.M.*, Dermody, T.S.*, Isaacs, S.N.*, Moyer, R.W.* “Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge” Vaccine Vol. 24:3686-94, 2006. [*co-principal investigators/senior authors]

Xiao, Y., Aldaz-Carroll, L., Ortiz, A.M., Whitbeck, J.C., Alexander, E., Lou, H., Davis, H.L., Braciale, T.J., Eisenberg, R.J., Cohen, G.H., Isaacs, S.N. "A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost" Vaccine Vol. 25:1214-1224, 2007.

Viner, K.M., Girgis, N., Kwak, H., Isaacs, S.N. "B5 deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals" Virology [in press]

Contact:
Stuart Isaacs, M.D.
502 Johnson Pavilion
University of Pennsylvania
Philadelphia, PA 19104-6073
isaacs@mail.med.upenn.edu
(215) 662-2150

Education:
Medical School: Yale University
ID Training: Tufts-New England Medical Center
Post-doctoral Research: National Institutes of Health, NIAID, Laboratory of Viral Diseases
Academic Rank: Associate Professor of Medicine